Gastric cancer has an incidence in North America of over 24,000 new cases annually, of which
approximately 15% are diagnosed at an early stage. Standard of care for early gastric cancer
(EGC) treatment has historically included anatomical resection with regional lymphadenectomy.
However, with the recent emergence of organ-sparing techniques, select patients with a very
low risk of lymph node metastases are able to avoid anatomical resection and its inherent
short and long term consequences. Despite this advance, EGC patients with high risk features
continue to require anatomical resection to achieve adequate lymph node staging, despite the
fact that 75-95% of these patients ultimately are found to have node negative disease. Due to
the inadequacy of standard imaging modalities to reliably detect nodal metastases in EGC
patients, sentinel lymph node sampling for gastric cancer was developed using principals
similar to those used broadly for breast and melanoma patients. Early reports from Asia
suggest this technique has very high success rates, accuracy and sensitivity, however it has
never been verified in a North American context. This study aims to test SLN sampling for
North American gastric cancer patients at a high volume regional treatment centre, with an
aim to expand the application of organ sparing resection to EGC patients.
This project aims to determine the sensitivity and accuracy of sentinel lymph node sampling
for early gastric cancer patients at a high volume, North American, tertiary care centre.
Phase:
N/A
Details
Lead Sponsor:
McGill University Health Center McGill University Health Centre/Research Institute of the McGill University Health Centre